SPEZIFIKATION
Investment of approximately 510 million yuan in a synthetic biotechnology project, marked by the signing of a landing agreement between Homology Biosciences (Shanghai) Co., Ltd. and Hefei High-tech Zone on February 4, 2026, officially settles in Hefei High-tech Zone.
The project covers a total area of 50 mu and will be constructed in two phases. Upon completion, it will become a leading domestic industrial production base for human milk oligosaccharides (HMOs). After full capacity is achieved in Phase II, the annual production capacity will reach 3,000 tons, with an estimated annual output value of 1.5 billion yuan.
Homology Biosciences is an innovative enterprise in the field of synthetic biology, incubated within the Mengniu Group system, focusing on the independent research and industrialization of human milk oligosaccharides (HMOs). The company is committed to breaking the long-term monopoly of international brands in this field and promoting the upgrading of domestic infant formula to a higher-end level. It is the first and only company in China to have obtained regulatory approval from the National Health Commission for three HMO products—2′-fucosyllactose (2′-FL), lacto-N-neotetraose (LNnT), and sodium 3′-sialyllactose (3′-SL)—and has passed the supplier review by leading domestic dairy companies.
In recent years, the high-tech zone has actively laid out the emerging sector of synthetic biology, currently gathering around 30 related enterprises such as Cathay Biotech, and establishing a full innovation chain covering basic research, pilot-scale amplification, and industrialization. By introducing special policies and guiding industry funds to work in coordination, the zone continues to optimize its industrial ecosystem and accelerate the cultivation of new growth drivers. Going forward, the high-tech zone will further deepen its development path of “strengthening and supplementing industrial chains, integrating key elements, and optimizing the ecosystem,” precisely attracting and nurturing key enterprises and critical projects along the upstream and downstream of the synthetic biology industry chain, providing full-lifecycle service support, and striving to build a synthetic biology industry hub with core competitiveness.
